Thromb Haemost 2013; 109(04): 583-584
DOI: 10.1160/TH12-11-0821
T&H Images
Schattauer GmbH

Resolution of giant left atrial appendage thrombus with rivaroxaban

Christoph Hammerstingl
1   Medizinische Klinik und Poliklinik II, Department of Cardiology, Angiology and Pneumology, University of Bonn, Bonn, Germany
,
Berndt Pötzsch
2   Institute for Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany
,
Georg Nickenig
1   Medizinische Klinik und Poliklinik II, Department of Cardiology, Angiology and Pneumology, University of Bonn, Bonn, Germany
› Author Affiliations
Further Information

Publication History

Received: 13 November 2012

Accepted after minor revision: 20 January 2012

Publication Date:
22 November 2017 (online)

 

 
  • References

  • 1 Ansell J, Hirsh J, Hylek E, Jacobson A. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 06) 160S-198S.
  • 2 Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor xa inhibitors. Circ Res 2012; 111: 1069-1078.
  • 3 Sinning JM, Ghanem A, Steinhauser H. et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv 2010; 03: 1141-1149.
  • 4 Bernhardt P, Schmidt H, Hammerstingl C. et al. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocar-diography and cerebral magnetic resonance imaging. Am J Cardiol 2004; 94: 801-804.